Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18941360 | 0.83 | BRD4 (0.56) | BRD4NPC1RAB9ALMNAMEN1 | |
| SCHEMBL23123 | 0.80 | BRD4 (0.64) | BRD4PDPK1NT5C2NT5EHTT | |
| SCHEMBL7264355 | 0.80 | BRD4 (0.67) | BRD4NT5C2NT5EHTT | |
| SCHEMBL8381773 | 0.79 | BRD4 (0.63) | BRD4PDPK1NT5C2NT5EHTT | |
| SCHEMBL8121389 | 0.78 | BRD4 (0.51) | BRD4PDPK1NT5C2NT5EHTT | |
| SCHEMBL18941373 | 0.77 | LMNA (0.33) | BRD4PDPK1POLBLMNAMEN1 | |
| SCHEMBL6463473 | 0.77 | BRD4 (0.60) | BRD4PDPK1NT5C2NT5EHTT | |
| SCHEMBL2514195 | 0.74 | BRD4 (0.47) | BRD4PDPK1NT5C2NT5EHTT | |
| SCHEMBL11023230 | 0.73 | BRD4 (0.52) | BRD4PDPK1NT5C2NT5EHTT | |
| SCHEMBL16618808 | 0.73 | NT5C2 (0.67) | BRD4PDPK1NT5C2NT5ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | claimed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | claimed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | claimed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | claimed |
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | disclosed |
| US-6380378-B1 | BIOSYNTHESIS | TOAGOSEI COMPANY, LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | disclosed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | disclosed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | BRD4 1684/4885PDPK1 116/4885NT5C2 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.